AI assistant
LEXICON PHARMACEUTICALS, INC. — Director's Dealing 2013
Feb 4, 2013
32814_dirs_2013-02-04_a87a4e3b-56e5-47c3-9fb9-e6a3491eb9ce.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LEXICON PHARMACEUTICALS, INC./DE (LXRX)
CIK: 0001062822
Period of Report: 2013-01-31
Reporting Person: MAIN ALAN J (EVP, Pharmaceutical Research)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-01-31 | Common Stock | M | 31600 | — | Acquired | 106127 | Direct |
| 2013-01-31 | Common Stock | F | 12537 | $2.11 | Disposed | 93590 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2013-01-31 | Restricted Stock Units (Phantom Stock) | $ | M | 31600 | Disposed | Common Stock (31600) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3: Restricted stock units vest with respect to 100% of the shares subject to the restricted stock unit upon the dosing of the first patient in a pivotal human clinical trial in any country, the results of which could be used to establish safety and efficacy of a pharmaceutical product discovered or developed by the Company (whether or not licensed by the Company to a third party) as a basis for a New Drug Application with the U.S. Food and Drug Administration or that would otherwise satisfy the requirements of 21 CFR 321.21(c) or its foreign equivalent.